News

Biogen to Acquire RayThera for up to $1 billion, capturing a pre-clinical small-molecule immunology pipeline before Phase 1 dosing...

Porosome Therapeutics Partners with India's CSIR to co-develop treatments across eight disease areas including Alzheimer's, cystic fibrosis, and COPD.

Acumen's Enhanced Brain Delivery candidates achieved 14-40x higher antibody concentrations in primate brains, advancing its Alzheimer's platform ahead of...

FDA accepts Outlook's LYTENAVA resubmission for wet AMD with Class 1 review status and a July 29, 2026 PDUFA...

Rigel Acquires Global Rights to Breast Cancer Drug VEPPANU for $70M just six weeks after FDA approval, targeting August...

Reunion Neuroscience names operator Sahil Kirpekar as CEO following luvesilocin breakthrough designation for postpartum depression treatment.

Setmelanotide pediatric hypothalamic obesity treatment showed 71% of patients improved by at least one weight category after one year,...

Scilex distributes Semnur Pharmaceuticals spinout on June 15, separating its sciatica-focused pipeline from commercial operations.

Intravacc and SynphaBase partner to address synthetic oligosaccharide supply and GMP manufacturing gaps in conjugate vaccine development.

60 Degrees Pharma licenses Australian Chestnut Extract from Florida State University for supplement development, pending FDA safety clarification.